TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

In a media briefing streamed live on Canada's Global News, Bonnie Henry, MD, BC's health officer, shared the latest investigation ... (Schnirring, 11/12) Novavax yesterday announced that the US Food ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Aerobic exercise has been linked with Parkinson's disease progression and risk. (Washington Post) Air purifiers in ...

U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

Cambridge: Moderna, Inc. has announced Health Canada has approved mRESVIA (Respiratory Syncytial Virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease ...

Canada has detected its first presumptive case of H5 bird flu in a person, a teenager in the western province of British ...

If you missed the early fall push for flu and COVID-19 vaccines, it's not too late.Health officials say it's important to get ...